AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca's revenue for the second quarter of 2023 was $11.42 billion, up 5% from the previous quarter and 6% from the second quarter of 2022. At the end of June 2023, AstraZeneca's total debt was about $30.8 billion, down $1.68 billion from the previous quarter. Calquence's revenue was $653 million in Q2 2023, up 33.55% year-on-year.

AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)

Pfizer

AstraZeneca plc (LON: AZN) was in focus on Friday after the pharma giant announced a deal worth up to $1.0 billion with its U.S. peer Pfizer Inc (NYSE: PFE). Details of the AstraZeneca-Pfizer deal The London-listed firm is buying a group of preclinical gene therapies from Pfizer to expand its footprint in rare diseases.

AstraZeneca reveals a $1.0 billion deal with Pfizer

AstraZeneca PLC (NASDAQ:AZN ) Q2 2023 Earnings Conference Call July 28, 2023 6:45 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fredrickson - Executive Vice-President, Oncology Business Unit Susan Galbraith - Executive Vice President, Oncology Research & Development Ruud Dobber - EVP of BioPharmaceuticals Business Unit Mene Pangalos - Executive Vice-President, BioPharmaceuticals R&D Marc Dunoyer - Chief Executive Officer, Alexion Leon Wang - Executive Vice-President, International & China President Conference Call Participants Sachin Jain - Bank of America Tim Anderson - Bernstein Andrew Baum - Citi Mark Purcell - Morgan Stanley Gonzalo Artiach - ABG Richard Parkes - Exane Christopher Uhde - SEB James Gordon - JPMorgan Emily Field - Barclays Victor Sanders - Nordea Steve Scala - Cowen Simon Baker - Redburn Seamus Fernandez - Guggenheim Matt Weston - Credit Suisse Eric Le Berrigaud - Stifel Peter Welford - Jefferies Luisa Hector - Berenberg Operator Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe, and good evening to those listening in Asia.

AstraZeneca PLC (AZN) Q2 2023 Earnings Call Transcript

AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications.

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales

AstraZeneca's shares rose on Friday after it announced the purchase of Pfizer's rare disease portfolio for up to $1 billion and reported better-than-expected financial results on strong sales of its cancer drugs.

AstraZeneca Shares Surge After Revenue Beat on Cancer Drug Sales, $1 Billion Pfizer Deal

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Astrazeneca (AZN) Q2 Earnings: A Look at Key Metrics

AstraZeneca PLC's (LSE:AZN) underlying quarterly performance shows it is "far from a one-trick pony" and its share price premium over peers is entirely warranted, broker Shore Capital said. Alongside the announcement of a US$1bn acquisition, second-quarter results from the biggest company on the FTSE 100 showed a stronger top line of U$11.4bn than consensus forecasts, up 6% as the unwinding of Covid-19 medicines created a drag.

AstraZeneca number show how it is 'not a one-trick pony' - analyst

BeiGene

Exelixis

Kura Oncology

Merck

Novartis

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.

7 Best Cancer Stocks to Invest in Now

Aradhana Sarin told CNBC the company was in a "very unique space" regarding impact from rising geopolitical tensions between China and the west.

AstraZeneca CFO denies geopolitics impacts the company's China business after spinoff rumors

AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful".

AstraZeneca CEO says lung cancer drug trial data 'very encouraging'

AstraZeneca PLC's rare disease unit, Alexion, has unveiled a $1 billion agreement to acquire Pfizer's early-stage gene therapy portfolio, a strategic move designed to bolster its footprint in the burgeoning field of genomic medicine. The deal, which is expected to be concluded in the third quarter, will bring Alexion a number of preclinical programmes and technologies, alongside a set of adeno-associated virus (AAV) capsids vital for gene therapy and editing.

AstraZeneca unit strikes $1bn rare diseases deal with Pfizer

AstraZeneca said on Friday its unit Alexion has agreed to buy a portfolio of U.S. drugmaker Pfizer's early-stage rare disease gene therapy for up to $1 billion, plus royalties on sales.

AstraZeneca signs $1 bln deal with Pfizer for gene therapy portfolio

AstraZeneca on Friday beat expectations for its second-quarter profit, helped by better-than-expected sales of its oncology drugs.

AstraZeneca second quarter profit beats expectations

NatWest Group plc 

A month ago NatWest Group PLC (LSE:NWG) would have expected a fairly calm set of interim results focusing on its UK and investment banking divisions. That was before Nigel Farage's Coutts account was closed, sparking a battle with the bank that ended with the toppling of boss Alison Rose.

NatWest adjusts to life after Rose, plus AstraZeneca and BA interims due on Friday

AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why AstraZeneca (AZN) Might Surprise This Earnings Season

AstraZeneca (LON: AZN) share price has struggled in the past few weeks as concerns about its cancer drug. After soaring to a record high of 12,350 in April, the stock has plunged by ~14% to 10,650, meaning it has moved into a correction.

AstraZeneca share price: death cross nears ahead of earnings

Certain industries have reduced their presence and or reliance on the Chinese market in 2023, but Big Pharma isn't one of them, according to reporting from the Wall Street Journal.  The company's aging population, an increasing share of the which is living with a chronic lifestyle disease, makes for an attractive market.

Big Pharma bets on China's aging population

Ameren

Biogen

CME Group

CNH Industrial NV

Genuine Parts

Intercontinental Exchange

iShares Trust iShares 1-5 Year Investment Grade Corporate Bond ETF

Itau Unibanco Holding S.A.

Cie Generale des Etablissements Michelin SCA

Mueller Industries

Paramount Global

Siemens AG

Sylvamo Corp

TEGNA

Target

Textron

Barron's Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies, of-which YCharts reported 25 as paying dividends. Barron's interviews with their ten financial-industry Roundtable pros tapped human intelligence (HI) to make predictions. Unfortunately, the YCharts screener employed to report current data, dropped seven funds off the list. Nevertheless, the Watchlist tracked by YCharts as of 7/19/23 projected ten top analyst-estimated net gains from ICE, PARA, TXT, AZN, MLI, BIIB, SIEGY, CHNI, TGNA, & topped by SLVM, ranging from 15.53%-31.31%.

4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys

In April, AstraZeneca PLC (LSE:AZN) hit an all-time high above £122 per share, topping former suitor Pfizer, before retreating sharply. It has been on the front foot in the weeks leading up to next Friday's quarterly update as investors have digested the disappointing news on a high-profile lung cancer study, where around £14bn was erased from its market value in one day, eventually reducing the shares to 17% of their earlier peak.

AstraZeneca earnings update comes with shares regrouping after big tumble from peak

Sanofi

WASHINGTON (AP) — U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.

New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season

The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution

Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis'

RSV in infants often leads to the development of pneumonia or bronchiolitis—conditions that can result in emergency visits.

FDA Approves Antibody For RSV After Challenging 2022 Season

The U.S. Food and Drug Administration on Monday approved a Sanofi SNY, +0.28% and AstraZeneca PLC AZN, -0.60% respiratory syncytial virus vaccine for newborns and infants. The RSV vaccine, Beyfortus, was approved for prevention of RSV lower respiratory tract disease in babies entering their first RSV vaccine as well as children up to two years old who remain vulnerable to severe RSV, the FDA said in a release.

FDA approves Sanofi and AstraZeneca infant RSV vaccine

While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S.

FDA Approves First RSV Drug to Protect All Infants

Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition. Nirsevimab is administered either before or during an infant's first RSV season.

FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV

News for AstraZeneca Stock (AZN)